Dorronsoro de Cattoni S T, Battellino L J
Cátedra de Química y Física Biológicas, Facultad de Odontología, Universidad Nacional de Córdoba, Argentina.
Acta Physiol Pharmacol Ther Latinoam. 1992;42(1):13-26.
The effects of i.p. piroxicam administration on hepatic glycogen levels and enzymatic activities of key enzymes involved into glycogen metabolism in fed female rats were studied. Liver glycogen concentrations in treated rats decreased with increasing time of treatment and doses of piroxicam administered. The fall in glycogen caused by piroxicam persisted for several days after it was discontinued. Neither nadolol nor phenobarbital administration were able to prevent the depleting effect of piroxicam. In the treated rats, glucose-6-phosphatase, glycogen phosphorylase and glycogen synthase activities remained unchanged respect to control. Also, proportion of phosphorylase in the active (a) form was not significantly affected by successive piroxicam daily doses. In contrast, we demonstrated a decrease in the glycogen synthase in the active I form. This reduction was time-dependent on piroxicam treatment. Further, glucose loads were not capable to restore activity in the synthase enzyme and liver glycogen synthesis in animals treated with piroxicam. The impairment into glycogen metabolism produced by piroxicam administration suggests liver becomes unable to maintain glucose homeostasis. Furthermore, glycogen depletion might produce an impairment in the metabolism of drugs administered simultaneously with piroxicam, because biotransformation of xenobiotics is a process depending on glycogen storage in the liver cells.
研究了腹腔注射吡罗昔康对喂食状态下雌性大鼠肝糖原水平以及糖原代谢关键酶活性的影响。随着治疗时间的延长和吡罗昔康给药剂量的增加,经治疗大鼠的肝糖原浓度降低。吡罗昔康导致的糖原下降在停药后持续了数天。给予纳多洛尔或苯巴比妥均无法预防吡罗昔康的消耗作用。在经治疗的大鼠中,葡萄糖-6-磷酸酶、糖原磷酸化酶和糖原合酶的活性与对照组相比保持不变。此外,连续每日给予吡罗昔康剂量对活性(a)形式的磷酸化酶比例没有显著影响。相比之下,我们发现活性I形式的糖原合酶减少。这种减少与吡罗昔康治疗时间有关。此外,葡萄糖负荷无法恢复经吡罗昔康治疗动物的合酶活性和肝糖原合成。吡罗昔康给药导致的糖原代谢受损表明肝脏无法维持葡萄糖稳态。此外,糖原耗竭可能会损害与吡罗昔康同时给药药物的代谢,因为外源性物质的生物转化是一个依赖于肝细胞中糖原储存的过程。